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Irreversible breakdown of cartilage extracellular matrix
(ECM) by the collagenase matrix metalloproteinase 13
(MMP13) represents a key event in osteoarthritis (OA) progres-
sion. Although inflammation ismost commonly associatedwith
inflammatory joint diseases, it also occurs in OA and is thus
relevant to the prevalent tissue destruction. Here, inflammation
generates a cFOS AP-1 early response that indirectly affects
MMP13 gene expression. To ascertain a more direct effect on
prolonged MMP13 production we examined the potential
molecular events occurring between the rapid, transient expres-
sion of cFOS and the subsequent MMP13 induction. Impor-
tantly, we showMMP13 mRNA expression is mirrored by nas-
cent hnRNA transcription. Employing ChIP assays, cFOS
recruitment to the MMP13 promoter occurs at an early stage
prior to gene transcription and that recruitment of transcrip-
tional initiation markers also correlated with MMP13 expres-
sion.Moreover, protein synthesis inhibition following earlyFOS
expression resulted in a significant decrease in MMP13 expres-
sion thus indicating a role for different regulatory factors mod-
ulating expression of the gene. Subsequent mRNA transcrip-
tome analyses highlighted several genes induced soon after FOS
that could contribute to MMP13 expression. Specific small
interfering RNA-mediated silencing highlighted that ATF3 was
as highly selective forMMP13 as cFOS.Moreover,ATF3 expres-
sion was AP-1(cFOS/cJUN)-dependent and expression levels
were maintained after the early transient cFOS response. Fur-
thermore, ATF3 bound the proximal MMP13 AP-1 motif in
stimulated chondrocytes at time points that no longer sup-
ported binding of FOS. Consequently, these findings support
roles for both cFOS (indirect) and ATF3 (direct) in effecting
MMP13 transcription in human chondrocytes.
Cartilage extracellular matrix (ECM)7 degradation within
synovial joints (especially knee, hip, hands, and spine) is a path-
ological process synonymous with patient disability and pain in
those suffering from either osteoarthritis (OA) or rheumatoid
arthritis (RA). In reality, OA and RA are not single diseases but
rather pathologies with various initiating factors that often
include inflammation; both diseases have the common end
point of irreversible destruction of the cartilage ECM.Although
more marked in RA, inflammatory mediators released by
immune cells (and joint tissue cells) orchestrate the aberrant
production of catabolic factors that initiate destruction in both
diseases. Numerous mediators including tumor necrosis factor
 (TNF), interleukin (IL)-17, and IL-1 have been reported to
constitute this inflammatory response (1, 2). Our own findings
have shown that suchmediators, when in combinationwith the
IL-6 family cytokines, oncostatin M (OSM) or IL-6 itself, pro-
motemarked expression of matrix metalloproteinases (MMPs)
(3–7), the enzymes known to be responsible for cartilage dam-
age. Potent expression of MMPs is therefore very likely within
most inflammatory milieux, including OA.
Of the MMPs, it is specifically the collagenases MMP1 and
MMP13 that are understood to cleave themain structural com-
ponent of cartilage, type II collagen, thus effecting the irrevers-
ible loss of ECM architecture and function. Current dogma
indicatesMMP1 (produced by synovial fibroblasts) to be key in
RA (predominantly a synovium-driven pathology), whereas
MMP13 (synthesized by chondrocytes) is the major effector
enzyme in OA, which is thought largely to be a cartilage-medi-
ated disease. Although this representation is somewhat over-
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simplified, both enzymes remain key therapeutic targets for dis-
ease-modifying agents (8).
Under normal physiological conditions, chondrocytes main-
tain normal cartilage ECM homeostasis to enable smooth, fric-
tionless joint articulation. In disease, a variety of stimuli such as
Toll-like receptor ligands and inflammatory cytokines (3, 6,
9–11) elicit intracellular signaling cascades in chondrocytes
that culminate in greatly increasedMMP13 expression. More-
over, epigenetic studies have shown promoter alterations such
as methylation status (12, 13) can further contribute to the ele-
vatedMMP13 expression, which is a hallmark of OA.
Regulation of eukaryotic gene expression represents a vital
control mechanism that ensures appropriate cellular function.
Transcriptional control can be supplemented at various levels,
including alterations in ribosome translational efficiency and
stability of mRNA transcripts and protein. Cartilage ECM pro-
teolysis is subject to further regulation, becausemostMMPs are
produced as inactive zymogens requiring proteolytic activation
for activity (14), and a family of endogenous inhibitors (tissue
inhibitors of metalloproteinases) provide additional control
over the activities of these potent enzymes. Considerable
research has focused on better understanding the molecular
mechanisms bywhich transcription ofMMPs is regulated, with
the activator protein (AP)-1 transcription factor being consid-
ered a key factor forMMPexpression (15–20). AP-1 is a protein
dimer expressed ubiquitously, and is comprised of a FOS
(cFOS, FOSB, FOSL1, FOS-like antigen (FRA)1 or FRA2) and
JUN (cJUN, JUNBor JUND) heterodimer or a JUNhomodimer.
Variations inAP-1 composition dictate specificity and allow for
differential gene regulation in specific tissues (21). Several stud-
ies including our own have confirmed AP-1 dependence for
MMP13 induction by diverse stimuli including phorbol ester,
parathyroid hormone, TNF, IL-1, and IL-17 (15–25),
whereas we and others (17–19, 23, 24), have indicated
cFOScJUN heterodimers are key regulators of MMP13 in
chondrocytes. Moreover, we have shown pro-catabolic stimuli
such as IL-1OSMmarkedly enhanceMMP expression com-
pared with IL-1 alone, both in vitro and in vivo (5–7, 19), with a
concomitant increase in FOS induction (19). However, despite
a functional role of FOS as an immediate early gene in regulat-
ingMMP13 expression via specific cell signaling pathways (18,
24–30), the complete mechanism underpinning transcrip-
tional activation of this MMP remains to be defined.
In this context several studies suggest other transcriptional
regulators may act, in concert with cFOScJUN, to effect
MMP13 transcription (23, 25, 27–29). To further understand
the regulation of MMP13 expression in the context of patho-
logical ECM turnover, we have assessed MMP13 transcrip-
tional regulation following a potent pro-catabolic stimulus
known to promote cartilage destruction (5, 6, 31). Here, we
demonstrate that cFOScJUNAP-1 is not the soleAP-1 contrib-
utor to the initiation of transcription of MMP13. We identify,
for the first time, that cFOScJUN also induces activating tran-
scription factor 3 (ATF3) to modulate MMP13 expression in
chondrocytes. These data indicate a further mechanism in reg-
ulating this gene that may aid in defining more potential ther-
apeutic targets to abrogate cartilage ECM degradation associ-
ated with OA.
Results
MMP13 Gene Expression Is Associated with an Early Induc-
tion of cFOS—We have previously reported that the potent
cytokine combination of IL-1OSM induces time-dependent
collagenolytic MMP13 expression, typically reaching maximal
induction at 24 h (31–33). We now confirm a detailed time
course forMMP13 induction in primary human articular chon-
drocytes, exhibiting detectable stimulation of mRNA expres-
sion fromaround 6hpost-stimulation (Fig. 1A). The expression
of MMP13 was associated with an early, rapid but transient
induction of FOS mRNA (Fig. 1B) as we have previously
reported (33). This was also reflected in detectable cFOS pro-
tein in the nuclear fraction at 1 h, which persisted up to 3–6 h
(Fig. 1, C and D), and was accompanied by cJUN phosphoryla-
tion (Fig. 1, E and F). These data are consistent with the prevail-
ing paradigm of cFOSphospho-cJUN dependence for proin-
flammatory cytokine induction ofMMP13 (18, 19, 21–25, 34).
Importantly, we verified that nascent hnRNA mirrored the
mRNA expression indicative of transcription of the gene inde-
pendent of mRNA synthesis/stability (Fig. 1G).
Enrichment of cFOS at the MMP13 Promoter Is an Early,
Transient Response Event—Initially, ChIP assays revealed that
cFOS enrichmentwas only detectable 1 h post-stimulation (Fig.
2A, inset), further suggesting an early, rapid but transient
recruitment of cFOS to this promoter region. Further assays
also confirmed enrichment of phospho-Ser5 RNAPol II (pRNA
Pol II) at the proximalMMP13 promoter 24 h post-stimulation
(Fig. 2B, inset), in line with mRNA/hnRNA expression at this
time point (see Fig. 1, A and B). In this context it is worthy to
note that Ser5 phosphorylation of RNAPol II has been shown to
be concentratednear thepromoter of genes,whereas Ser2 phos-
phorylation of RNAPol II is observed throughout the gene (35).
Consequently, no enrichment in the 3-UTR of MMP13 was
observed in the assays presented herein (see Fig. 2B). Assays
employing an anti-acetyl(Lys9/14)-histone H3 antibody indi-
cated histone H3 was acetylated at theMMP13 promoter at all
time points (Fig. 2C) thus allowing appropriate regulation of
transcription of the gene.
Although there was a requirement for MMP13 induction
by IL-1  OSM via cFOS, the delay in transcription of
hnRNA/mRNA combinedwith the rapid turnover of cFOS (see
Fig. 1B–D) (36) indicated that other AP-1 regulators were syn-
thesized following FOS induction, and thus contribute to tran-
scription of the gene. A role for de novo protein formation was
confirmed, after the early induction of cFOS, employing the
protein synthesis inhibitor emetine. Here, 24 h IL-1  OSM-
stimulated cells were incubated with the inhibitor andMMP13
mRNA expression subsequently monitored. Emetine was
observed to significantly reduce MMP13 expression, which
persisted up to 6–8 h post-stimulation (see Fig. 2D). Conse-
quently, IL-1  OSM stimulation and induction of cFOS
p-cJUN heterodimers promote the rapid formation of tran-
scriptional regulator(s), which further drive MMP13 expres-
sion. To determine these novel regulators, genome-wide
microarray analyses were performed on primary chondrocyte
populations stimulated at specific timepointswith IL-1OSM
and whereMMP13 induction occurred at 24 h. Analysis of the
ATF3ModulatesMMP13 Expression
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data confirmed that the 24-h time point had the highest num-
ber of changes in gene expression relative to basal (Fig. 3,A and
B) as previously reported for a chondrocyte cell line (33). Fur-
thermore, ingenuity pathway analysis of the 24-h dataset high-
lighted multiple proinflammatory signaling pathways, includ-
ing IL-1, IL-17, andTNF (see supplemental Table S1), aswell
ATF3ModulatesMMP13 Expression
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as multiple regulators and upstream regulators (supplemental
Tables S2 and S3), indicating that IL-1  OSM is indeed a
potent model proinflammatory stimulus. Although heat maps
(Fig. 3A) indicated relatively few changes in gene expression at
the earlier time points; marked induction of several transcrip-
tional regulators, including FOS, JUN, and ATF3, was observed
at 1 (Fig. 3C) and 1.25 h (Fig. 3D). Strikingly, FOSwas one of the
most highly induced genes at 1 h (Fig. 3C), which almost halved
by 1.25 h (Fig. 3D) and was one of the most highly down-regu-
lated genes at 24 h (Fig. 3E) further illustrating the transient
nature of FOS expression.MMP13 expressionwas detectable at
24 h but barely detectable at the early time points (Fig. 3, F and
G), correlating with the transient expression profile of FOS and
the more sustained expression of ATF3 (see Figs. 3F and 4).
Furthermore, JUN expression was elevated and sustained at
both 1 and 1.25 h (Fig. 3,C andD), whereas data from the arrays
also indicated increased expression from 1 to 1.25 h of FOSL1,
FOSB, JUNB, RELA (p65), immediate early responsive gene 3
(IER3), and interferon regulatory factor 1 (IRF1), which were all
confirmed by real-time RT-PCR in multiple chondrocyte pop-
ulations (Fig. 4). Subsequent siRNA assays were employed to
determine the effect of knockdown of these and cFOScJUN
transcriptional regulators on MMP13 expression in chondro-
cytes stimulated with IL-1  OSM. Here, knockdowns of not
only FOS/FOSL1 but also ATF3 resulted in substantial inhibi-
tion ofMMP13 expression (p  0.0001 compared with siRNA
controls (see Table 1)).
Prolonged Expression of ATF3ModulatesMMP13Transcrip-
tion—The above siRNA data thus implicated a potent role for
ATF3 in regulating MMP13 expression. Temporal expression
of ATF3 in IL-1  OSM-treated cells was thus determined to
observe any overlap with FOS expression. Here, ATF3 mRNA
and nuclear protein was significantly increased at 1 h butmain-
tained up to 24 h (see Fig. 5,A-C) in contrast to FOS expression
(Fig. 1, B-D) where levels decreased substantially after 1 h.
siRNAs knockdowns of FOS/JUN in IL-1  OSM-stimulated
cells were subsequently employed to determine any association
with ATF3 expression. Knockdown of both FOS and JUN
mRNA significantly reduced ATF3 mRNA levels (Fig. 5D).
Control Western blots on nuclear extracts confirmed siRNA
knockdowns of cFOS and phospho-cJUN was also mirrored at
the protein level, where the latter also reflected total cJUN lev-
els (see Fig. 5E). DNA affinity precipitation assays (DAPAs)
were subsequently performed on IL-1OSM-stimulated cells
to ensure that the temporal binding of cFOS and ATF3 to the
MMP13 proximal promoter AP-1 element was reflective of
their respective transient and sustained levels of expression.
Here, specific AP-1 oligonucleotide-protein binding was
initially determined in the presence of 50 excess non-bio-
tinylated AP-1 oligonucleotide (data not shown). Further
DAPAs confirmed the ability of both of these factors to bind
at 1 h; whereas only ATF3 was still bound to this element 6 h
post-stimulation (Fig. 6A). This was associated with the
maintained expression of ATF3 at 6 h in contrast to the
observed decreased expression of cFOS (see Fig. 6B,Western
blot input).
Discussion
Proinflammatory cytokines that are associated with cartilage
destruction and arthritis have been extensively reported by sev-
eral groups including our own (6, 7, 9, 37, 38). In this context,
cytokine combinations such as IL-1  OSM represent highly
useful model stimuli to study complex inflammatory mecha-
nisms in arthritis, promoting cartilage breakdown (9, 31,
38–41) that correlates with significantly enhanced collag-
enolyticMMP expression (4–7, 18, 19, 30–33). Indeed, inge-
nuity pathway analysis of the 24-h time point indicated that
the stimulus of IL-1  OSM up-regulated numerous genes,
many regulators of gene expression, associated with various
other proinflammatory stimuli such as IL-1, IL-17, and
TNF, indicative of IL-1  OSM being a potent model pro-
catabolic stimulus.
Such cytokine-mediated inflammation is an important con-
tributory factor for arthritis initiation and progression. This is
the case not only in RA, where anti-cytokine biologics are now
a key part of therapeutic strategies (41), but is also increasingly
recognized in OA (2). Pathological inflammatory milieux are
unlikely to comprise only a singlemediator and so induction via
several cytokines may be common; this may explain, in part,
how relatively low level joint inflammation can nevertheless
perpetuate cartilage destruction. Thus, the cytokine-stimu-
lated molecular pathways and regulators that drive the
expression of collagenolytic MMPs are likely to be common
to many proinflammatory stimuli and therefore potential
therapeutic targets.
MMP13 is thought to be the key collagenase in OA (8).
Despite a confirmed role for AP-1 in the transcriptional activa-
tion of manyMMP genes, includingMMP13 (13, 15–19), there
is a temporal discord between the expression of the rapid FOS
response (typically 30–60 min) and the subsequent expression
of collagenolytic MMPs (typically from 6 to 24 h). We have
previously confirmed a role for cFOScJUN AP-1 regulators in
MMP13 transcription (18, 19), and here further demonstrate
the rapid, early but transient induction of FOS in human chon-
drocytes. ChIP assays, performed at a time when MMP13
mRNA was maximally detectable (24 h) confirmed no enrich-
ment of cFOS to the proximal promoter region of the gene,
although recruitment of phospho-Ser5 RNA Pol was observed
at 24 h. This confirms there is indeed a delay between the time
of FOS expression and when the MMP13 gene is transcribed.
FIGURE 1. IL-1OSM-stimulatedMMP13mRNA expression is preceded by nascent hnRNA formation and involves early induction of cFOS in human
chondrocytes. Chondrocytes were stimulated with IL-1 (0.05 ng/ml) in combination with OSM (10 ng/ml) for the indicated durations. Total RNAwas isolated,
reverse transcribed, and subjected to real-time RT-PCR forMMP13mRNA (A), cFOSmRNA (B), orMMP13 nascent hnRNA (G) as described under “Experimental
Procedures.” Data are expressed relative to 18S rRNA and presented as fold-increase comparedwith basal expression. PCR data (n 4) are representative of at
least three separate chondrocyte populations. Cells were subjected to subcellular fractionation and protein from the cytosolic (a), membrane-bound (b),
soluble nuclear (c), chromatin-bound, (d) and cytoskeletal (e) fractions resolved using SDS-PAGE and immunoblottedwith antibodies to cFOS (C) or phosphor-
ylated cJUN (E). Combined densitometric scans of five separate blots for each protein in the soluble nuclear fraction, relative to t 0 h, are shown in D and F,
respectively, andwere obtained from separate chondrocyte populations. All data are presented asmean ( S.D.), where ***, p 0.001; **, p 0.01; *, p 0.05
IL-1 OSM-treated compared with control; ANOVA.
ATF3ModulatesMMP13 Expression
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FIGURE 2. ChIP analyses of theMMP13 proximal promoter. Human chondrocytes were treated with IL-1 (0.05 ng/ml) in combination with OSM (10 ng/ml)
for the indicated durations. Cells were then subject to DNA-protein cross-linking, lysis, and DNA shearing. Immunoprecipitation for cFOS (A), pRNA Pol II (B), or
AcH3 (C) was followed by isolation of complexed genomic DNA and subsequent real-time RT-PCR for the proximal (closed bars) and 3-UTR (used for normal-
ization; open bars) regions ofMMP13 as indicated. Data (mean S.D.) are pooled from three (five for inset data) separate chondrocyte populations. Statistical
comparisons are: *, p 0.05 (24 h IL-1OSM stimulation versusbasal); #, p 0.05 (1 h IL-1OSM stimulation versusbasal).D, chondrocyteswere treatedwith
IL-1 (0.05 ng/ml) andOSM (10 ng/ml) for 24 h. Emetine (10M final concentration)was added at the indicated times after IL-1OSM stimulation and real-time
RT-PCR performed on extracted RNA relative expression levels of MMP13 mRNA were normalized to 18S rRNA, where ***, p 0.001 (IL-1 OSM emetine
versus basal); ###, p  0.001 (IL-1OSM versus basal). Data (mean  S.D., n  6) are representative of three separate experiments each using chondrocyte
cultures from different donors.
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FIGURE 3. IL-1  OSM stimulation induces expression of several transcriptional regulators prior to MMP13 expression. Human chondrocytes were
treated with IL-1 (0.05 ng/ml) in combination with OSM (10 ng/ml) for the indicated time points and total RNA isolated. A–F, RNA from three separate
populations (numbers 1, 2, and 3) was profiled using the Human HT-12v4 Expression Beadchip. A heat map of all significantly regulated genes is presented. It
should be noted that the modest differences in gene expression between 1 and 1.25 h are reflected in these time points being grouped by chondrocyte
population (A). Volcanoplots are presenteddepicting genes significantly regulated2-fold, as indicatedby the vertical dotted lines, at 24 (B), 1 (C), and 1.25 h
(D), aswell as aplot of change in fold-expression from24 versus1h (E): genes of note arehighlighted in red. F, expressionprofiles forMMP13, FOS, andATF3 from
themicroarray dataset for each chondrocyte population are shown. G, RNA from six separate chondrocyte populations was subjected to real-time RT-PCR for
MMP13, and relative expression levels (normalized to 18S rRNA) at the indicated times determined. The plots show mean  S.D. (n  4). Data from the
populations used in the microarray analyses are highlighted by the solid symbols (#1, Œ; #2 f; #3,●).
ATF3ModulatesMMP13 Expression
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Although cFOS was recruited transiently to the promoter at
early time points, no pRNA Pol II was detected thus suggesting
the gene remained transcriptionally silent but potentially
poised as acetylation of H3-histones was observed at all time
points studied. This indicates that at early time points, recruit-
ment of a cFOScJUN AP-1 complex may not be sufficient to
effectMMP13 gene transcription. Moreover, this suggests that
further transcriptional regulators are required for the marked
MMP13 expression observed following IL-1  OSM stimula-
tion. Inhibition of protein synthesis after IL-1OSM stimula-
tion and, importantly, following expression of cFOS protein (as
well as cJUN phosphorylation) confirmed a role for the subse-
quent expression of different regulatory proteins in the tran-
scriptional activation ofMMP13. To determine these effectors,
genome-wide microarray analyses of stimulated human chon-
drocytes was employed: this confirmed that FOSwas one of the
most highly induced genes following IL-1  OSM stimulation
at 1 h, and that this expression was very transient. Although
heat maps indicated relatively few changes in gene expression
TABLE 1
MMP13 induction is primarily dependent on FOS familymembers and
ATF3 following IL-1OSM stimulation of chondrocytes
Prior to stimulation with IL-1 (0.05 ng/ml) in combination with OSM (10 ng/ml),
human chondrocytes were transfected with siRNA specific for the indicated genes,
or a non-targeting control (siCon; all 100 nM), andmRNAexpression levels (mean
S.D., n 6) ofMMP13 were measured at 24 h post-stimulation, relative to siCon-
treated cells, normalized to 18S rRNA. The percentage inhibition of MMP13
expression relative to IL-1  OSM  siCon was then calculated. Statistical com-
parisons are versus IL-1  OSM  siCon (Student’s two-tailed unpaired t test),
where ****, p 0.0001; ***, p 0.001; **, p 0.01; *, p 0.05. The data are pooled
from three separate experiments, each using chondrocyte cultures from different
donors.
Gene (siRNA)
MMP13
% Inhibition p value
 S.E.
ATF3 42.4 (15.2) ****
cFOS 42.2 (9.5) ****
FOSB 29.8 (19.9) **
FOSL1 39.1 (8.9) ****
IER3 18.4 (11.7) *
IRF1 19.5 (14.8) *
JUN 23.9 (13.3) **
RELA 17.7 (10.9) *
FIGURE 4. Expression of potential transcriptionalMMP13 regulators following IL-1 OSM stimulation. Six separate human chondrocyte populations
were treated with IL-1 (0.05 ng/ml) in combination with OSM (10 ng/ml) for the indicated durations. Total RNA was isolated, reverse transcribed, and
subjected to real-time RT-PCR for the indicated genes as described under “Experimental Procedures.” Data are expressed relative to 18S rRNA and
presented as fold-increase compared with basal expression (mean  S.D., n  4). Note: the same symbols have been used as in Fig. 3E to denote
individual populations.
ATF3ModulatesMMP13 Expression
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between 1 and 1.25 h, probably reflecting in part the heteroge-
neity of primary chondrocyte populations, several genes
(encoding known modulators of gene transcription) were nev-
ertheless expressed at 1 h and appeared to have a more sus-
tained gene expression profile at 1.25 h. These included ATF3,
FOSL1, FOSB, JUNB, RELA, IER3, and IRF1. However, siRNA
knockdowns of these factors indicated that only FOS family
members and ATF3 had the most potent inhibitory effect on
MMP13 expression. It is most probable that both FOSB and
FOSL1 could also contribute to AP-1-dependentATF3 expres-
sion, but herein we have focused on cFOS as this is considered
a primeAP-1 effector protein forMMP expression (15–25) and
silencing of this AP-1 member had the most marked effect on
MMP13 induction. Our data thus implicate an important role
for ATF3 in affecting MMP13 expression subsequent to the
transcription of FOS. Expression of ATF3 at both the mRNA
and protein levels indicated increased expression at the early
1-h time point as for cFOS but in contrast this was sustained
over 24 h where maximum MMP13 levels were observed.
Importantly, siRNA knockdowns of both FOS and JUN signifi-
cantly reduced ATF3 expression, further confirming a tran-
scriptional relationship between these factors and the contin-
ued expression of ATF3 in regulating MMP13 transcription.
ATF3, like other bZIP transcriptional regulators, can formboth
homo- or heterodimers to either activate or repress gene
expression, and inmany instances is dependent on cell type and
the promoter sequence of the target gene (42, 43). Indeed, the
proximal AP-1motifs forMMP1 andMMP13 are different, and
whereas silencing ATF3 reduced MMP13 expression sug-
gesting a transcriptional activator role, MMP1 expression
FIGURE 5. IL-1OSM induces sustained expression ofATF3, which is cFOS/cJUN-dependent. A, human chondrocytes were treatedwith IL-1 (0.05 ng/ml)
in combination with OSM (10 ng/ml) for the indicated durations. Total RNA was isolated, reverse transcribed, and subjected to real-time RT-PCR for ATF3 as
described under “Experimental Procedures.” Data are expressed relative to 18S rRNA andpresented as fold-increase comparedwith basal expression (mean
S.D., n  4). All data are representative of three separate experiments each using chondrocyte cultures from different donors. B, cells were subjected to
subcellular fractionation and proteins from the cytosolic (a), membrane-bound (b), soluble nuclear (c), chromatin-bound (d), and cytoskeletal (e) fractions
resolved using SDS-PAGE and immunoblottedwith an antibody to ATF3. C, relative density (comparedwith t 0 h) data of combined densitometric scans for
the soluble nuclear fractions of three separate blots (mean  S.D.) are presented. All statistical comparisons are IL-1  OSM-treated compared with basal
(ANOVA), where ***, p 0.001; **, p 0.01. D, human chondrocytes were treated with IL-1 (0.05 ng/ml) in combination with OSM (10 ng/ml) for 1.25 h. Prior
to stimulation, chondrocytes were transfected with siRNA specific for FOS, JUN, or a non-targeting control (siCon; all 100 nM). Following stimulation, total RNA
was isolated, reverse transcribed, and subjected to real-time RT-PCR for ATF3. Data are expressed relative to 18S rRNA and plotted relative to the IL-1OSM
siCon stimulation (set to 100%;mean S.D.,n8). Statistical comparisons are specific siRNA versus siCon (ANOVA),where ***,p0.001; **,p0.01. E,nuclear
fractions were also isolated following stimulation and immunoblotted for cFOS and p-cJUN*S63 or the soluble nuclear marker protein lamin A/C to assess
protein expression following siRNA knockdown.
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was unaffected.8 Futhermore, binding to the proximal AP-1
promoter element of MMP13 was observed for both cFOS
and ATF3 at the early 1-h time point with only ATF3 bound
at the much longer time point of 6 h. Consequently, these
studies provide strong evidence that ATF3 is transcription-
ally dependent upon the initial inflammation-induced
expression of cFOScJUN so as to mediate prolonged
MMP13 expression. In this context, ATF3 is a well established
stress-inducible gene (44), considered a hub for cellular adapt-
ive responses (44, 45), which has previously been shown to be
involved in chondrocyte differentiation (46). Moreover, very
recent studies have shown that ATF3 regulates AP-1-depen-
dent gene expression in murine osteoclast precursors (47),
and that increased expression of ATF3 in mouse and human
chondrocytes is a prime mediator of OA development (48).
Importantly, deletion of ATF3 was observed to abrogate the
onset of OA (48). In conclusion, data presented herein indi-
cate that cytokine-induced expression of MMP13 is depen-
dent on the initial transient formation of cFOScJUN dimers,
which subsequently promote sustained formation of ATF3
to modulate expression of the gene.
Experimental Procedures
Materials—All chemicals were obtained from Sigma (Poole,
UK) unless otherwise stated and of the highest purity available.
All cytokines were recombinant human. IL-1 was a generous
gift from Dr. Keith Ray (GlaxoSmithKline, Stevenage, UK).
OSMwas prepared in-house as described (49). siRNA reagents
were screened for toxicity using theToxilight assay of adenylate
kinase release (Lonza, Wokingham, UK).
Chondrocytes—Human chondrocytes were isolated by enzy-
matic digestion of intact articular cartilage from OA patients
undergoing joint replacement surgery as described (50). All
subjects gave informed consent and the study was approved
by the Newcastle and North Tyneside Joint Ethics Commit-
tee. Chondrocytes were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum,
100 IU of penicillin, 100 g/ml of streptomycin, 40 units/ml
of nystatin.
Cell Fractionation and Immunoblotting—Chondrocyte
lysates were prepared as described previously (30, 50). In some
experiments chondrocytes were subjected to subcellular frac-
tionation using the NE-PER Nuclear and Cytoplasmic Protein
Extraction Kit or Subcellular Protein Fractionation Kit (both
from ThermoFisher Scientific, Loughborough, UK). Lysates or
fractions were resolved by SDS-PAGE, transferred to PVDF
membranes, and subsequently probed with the following anti-
bodies: laminA/C (number 4777) was purchased fromCell Sig-
naling Technology (Danvers, MA); cFos (sc7202), cJun*S63
(sc7980), and ATF3 (sc188) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA).
Cell Transfection and RNA Interference—Primary human
chondrocytes were prepared and cultured as above, and
transfected as described previously (30). As an initial screen
for modulation of MMP13 expression, Qiagen FlexiPlate
small interfering RNA (siRNA) reagents were used. Dharma-
con ON-TARGETplusTM SMARTpools (ThermoFisher Sci-
entific) of 4 specific siRNAduplexes (total of 100 nM siRNA; see
supplemental Table S1) were used for follow-up studies where
appropriate; silencing efficacy was 90% as assessed by West-
ern blotting (data not shown). After transfection, cells were
stimulated for 1.25 h to measure expression of transcriptional
regulators, or 24 h for MMP genes. Changes in mRNA expres-
sion were calculated by comparison with cells transfected with
100 nM siCONTROL (siCon: non-targeting siRNA #2, catalog
number 001210-02; Dharmacon).
Chromatin Immunoprecipitation (ChIP)—ChIP experiments
were performed according to the standard protocol detailed in
the EZ-ChIP kit (Merck-Millipore). Briefly, human chondro-
cytes were cultured until 70–80% confluent, at which point
they were treated with IL-1 (0.05 ng/ml) in combination with
OSM (10 ng/ml) for various durations. Cellular components
were then cross-linked using formaldehyde for 5 min with agi-
tation, and the reaction quenched with 0.125 M glycine for 5
min (with agitation). Cells were then washed twice and scraped
into PBS supplemented with protease inhibitors. Cells were
pelleted, resuspended in lysis buffer, and lysates were sonicated
in a Bioruptor Plus (Diagenode) sonicating water bath (15
cycles of 30 s on, 30 s off; full power) to shear chromatin. Sam-
ples were then pre-cleared with the appropriate agarose beads
for 1 h and subjected to overnight immunoprecipitation with
relevant antibodies (10 g) or corresponding isotype controls:
anti-phospho-RNA polymerase II CTD repeats YSPTSPS (Ser5
pRNA Pol II; ab5131: Abcam, Cambridge, UK), anti-acetyl-
(Lys9/14)-histone H3 (AcH3, number 06-599; Millipore,
Dundee, UK), and anti-cFos (Santa Cruz). Antibodyprotein
DNAcomplexeswere extractedwith agarose beads andwashed
sequentially with kit-supplied buffers. DNA was then eluted
and cross-links reversed (4 h incubation at 65 °Cwith 5 MNaCl,
and then a 1-h incubation at 37 °Cwith RNase and proteinase K
to degrade RNA and protein, respectively). DNA was purified
by spin column and then used as input for SYBR Green real-
time PCR, using the following MMP13 primers: proximal
promoter/transcription start site: For, 5-GAAAAAGTCGC-
CACGTAAGC-3 and Rev, 5-CGACAATGAGTCCAG-
8 C. D. Macdonald, G. J. Litherland, G. N. Europe-Finner, and A. D. Rowan,
unpublished data.
FIGURE 6.ATF3, but not cFOS, binds the proximalMMP13AP-1motif at a
transcriptionally active time point in IL-1  OSM-stimulated chondro-
cytes. Human chondrocytes were treated with IL-1 (0.05 ng/ml) in combina-
tion with OSM (10 ng/ml) for the durations indicated. Nuclear lysates were
prepared and subjected to either DAPAwith the ATF3 or cFOS antibodies (A)
or Western blotting alone (input) (B), as described under “Experimental Pro-
cedures.” All data are representative of three separate experiments each
using chondrocyte cultures from different donors.
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CTCAA-3; 3-untranslated region (3-UTR): For, 5-TCGG-
CACAAAATACAGGTCA-3 and Rev, 5-GCCTCCCCTT-
TTTAGACCAC-3. Data were normalized to background
using isotype-control antibodies and variations in amount of
DNA were normalized using the percent input method and
shown as fold-change over basal in unstimulated cells at t 0 h.
DAPA—Chondrocyte nuclear lysates were generated as
described above (ThermoFisher Scientific). Nuclear protein (80
g) was incubated with double-stranded biotinylated oligonu-
cleotide (35 pmol) containing the proximalMMP13AP-1 bind-
ing site (5-[biotin]-TAAGTGATGACTCACCATTGC-3;
5-GCAATGGTGAGTCATCACTTA-3) in 500 l of binding
buffer (12 mM HEPES, pH 7.9, 4 mM Tris-HCl, 60 mM KCl, 5%
(w/v) glycerol, 0.5 mM EDTA, 1 mM DTT, and 1 mini-protease
inhibitor mixture tablet (Roche)/10 ml of buffer) for 45 min at
4 °C. Streptavidin-coated agarose beads, pre-cleared with BSA,
were then added and incubated for 2 h with rotation at 4 °C.
Beads were pelleted by brief centrifugation, supernatants
were discarded, and pellets washed three times with 1 ml of
binding buffer for 5 min at 4 °C with rotation. Beads were
finally resuspended in 50 l of sample buffer, incubated at
100 °C for 5 min, pelleted, and supernatants removed for
SDS-PAGE (as above).
Gene Expression Analyses—RNA was typically stabilized in
cell lysates in a 96-well format and cDNA synthesized using the
Cells-to-SignalTM kit (Life Technologies) as directed. Real-time
PCR assays were conducted using primers (30) and conditions
described previously (18, 34). TaqMan assays used Universal
Probe Library probes (Roche Applied Sciences) as directed (see
supplemental Table S4). Nascent hnRNA transcript expression
of MMP13 was determined via reverse transcription and Taq-
Man (37) employing 5-AGCACCCTTCTCATGACCTC-3
(For) and 5-TCCCCTGGTCTTGTGTGAG-3 (Rev) primers
spanning the Exon7/Intron7 boundary with probe number
82.
For genome-wide analyses, RNAwas isolated from chondro-
cytes using RNeasy Mini Kit (Qiagen, Crawley, UK) according
to the manufacturer’s protocol. RNA from three individual
patient samples was stimulated with IL-1  OSM for three
durations. Changes inwhole genome expressionwere then pro-
filed using the Human HT-12v4 Expression Beadchip (Illu-
mina, SaffronWalden, UK). Amplification, labeling, hybridiza-
tion, and detection were all performed by Cambridge Genomic
Services (Cambridge University, UK). Raw expression data
(GEO accession GSE86578) were analyzed using Agilent Gene-
Spring GX11 (Agilent Technologies, Santa Clara, CA). Raw
data were normalized with a quantile algorithm and the base-
line transformed to the median of all samples. Relative gene
expression of the probe set was determined by normalizing raw
expression values for each probe set to the unstimulated con-
trol from each chondrocyte population. The selection of genes
for further investigation was based on detailed functional anal-
ysis of statistically significant gene expression performed with
Ingenuity Pathways Analysis (Ingenuity Systems). Analysis of
RNA expression data in the context of known biological
response and regulatory networks allowed for the identification
of genes with relevant biological function.
Statistical Analyses—Statistical differences between sample
groups were assessed using one-way analysis of variance
(ANOVA) with a post hoc multiple comparison test or
Student’s two-tailed unpaired t test, where ****, p 0.0001; ***,
p  0.001; **, p  0.01; *, p  0.05. For clarity, only selected
comparisons are presented in some figures.
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